Effects of Labisia pumila on bone turnover markers and OPG/RANKL system in a rat model of post-menopausal osteoporosis

OBJECTIVE: To assess bone turnover markers (BTM) and bone mineral density (BMD) after discontinuation of alendronate treatment used for five or more years. SUBJECTS AND METHODS: 40 patients (pt) with post-menopausal osteoporosis treated with alendronate (10 mg/d) for at least five years (Group 1, G1) had their medication discontinued. Group 2 (G2): 25 pt treated with alendronate for at least one year. Group 3 (G3): 23 treatment-naïve osteoporotic pt. BMD was evaluated in G1 and G2 at baseline and after 12 months. Collagen type I cross-linked C-telopeptide (CTX) and procollagen type 1 N-terminal propeptide (P1NP) levels were measured in all pt at baseline, and in G1 and G2 every three months for 12 months. Data were analyzed using ANOVA on ranks and Mann-Whitney tests. RESULTS: Mean BMD values in G1 and G2 did not differ during follow-up. However, 16 pt (45.7%) in G1 and one (5.2%) in G2 lost BMD (P < 0.001). BTM at baseline was not different between G1 and G2, and both were lower than G3. A significant increase in BTM levels was detected in G1 pt after three months, but not in G2. CONCLUSION: Observed BMD loss and BTM rise after alendronate withdrawal imply that bone turnover was not over suppressed, and alendronate discontinuation may not be safe.

Download Full-text

Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women

Journal of Bone and Mineral Metabolism ◽

10.1007/s00774-013-0558-2 ◽

2014 ◽

Vol 33 (1) ◽

pp. 93-100 ◽

Cited By ~ 7

Author(s):

Shinichi Nagase ◽

Michiyo Ohyama ◽

Yoshitaka Hashimoto ◽

Maria Small ◽

John Sharpe ◽

...

Keyword(s):

Bone Turnover ◽

Sustained Release ◽

Bone Turnover Markers ◽

Cathepsin K ◽

Release Formulation ◽

Sustained Release Formulation ◽

Cathepsin K Inhibitor ◽

Menopausal Women ◽

Turnover Markers ◽

Post Menopausal

Download Full-text

Osteoprotegerin: a valid new marker of bone turnover in post-menopausal osteoporosis?

Journal of Orthopaedics and Traumatology ◽

10.1007/s10195-005-0087-4 ◽

2005 ◽

Vol 6 (2) ◽

pp. 88-90

Author(s):

F. M. Ulivieri ◽

L. P. Piodi ◽

D. Marchelli ◽

C. Corradini ◽

C. Verdoia ◽

...

Keyword(s):

Bone Turnover ◽

Post Menopausal Osteoporosis ◽

Post Menopausal ◽

Menopausal Osteoporosis

Download Full-text

Reversal of adverse effects of neoadjuvant chemotherapy on bone turnover in pre- and post-menopausal women with zoledronic acid

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.556 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 556-556

Author(s):

R. Aft ◽

M. Naughton ◽

K. Trinkuas ◽

M. Watson ◽

K. Weilbaecher

Keyword(s):

Zoledronic Acid ◽

Growth Factor ◽

Neoadjuvant Chemotherapy ◽

Bone Turnover ◽

Bone Turnover Markers ◽

Mineral Density ◽

Menopausal Women ◽

Turnover Markers ◽

Post Menopausal ◽

The Impact

556 Background: Ovarian failure secondary to adjuvant chemotherapy is known to have an adverse effect on bone mineral density and to increase bone turnover markers. The effects of chemotherapy with growth factor support in the absence of hormonal changes have not been described. The impact of zoledronic acid on these changes was also explored. Methods: We evaluated bone turnover markers in 82 women undergoing neoadjuvant chemotherapy for localized stage II/III breast cancer at initial diagnosis prior to treatment and after 4 cycles of epirubicin (75mg/m2)-docetaxel (75mg/m2) with pegylated G-CSF support with or without zoledronic acid. 47% of patients were post-menopausal and all groups were balanced for other variables. Women were randomized to receive zoledronic acid 4 mg IV every 3 weeks concurrently with chemotherapy (n=41) versus no bisphosphonate treatment (n=41). Bone turnover markers included: urinary N-telopeptide (NTx), serum bone specific alkaline phosphatase (BAP)and osteocalcin (OSTEO). Results: Women, regardless of menopausal status, who received no bisphosphonate had statistically significant increases in NTx, from baseline after 3 months of neoadjuvant chemotherapy using multivariable mixed repeated measures (p=0.0213). Women who received zoledronic acid concurrently with neoadjuvant chemotherapy had statistically significant decreases in NTx (p<0.0001), BAP (p<0.0001) and OSTEO (p=0.0295) from baseline. This is the first demonstration that anthracycline-taxane chemotherapy with growth factor support increased bone turnover markers in both post-menopausal and pre-menopausal women independent of hormone therapy, radiation therapy and surgery. Conclusions: Neoadjuvant chemotherapy with anthracycline- taxane and growth factor support increased bone resorption markers in both post-menopausal and pre-menopausal women. Zoledronic acid given concurrently with each cycle of chemotherapy reversed this increase in bone turnover markers. No significant financial relationships to disclose.

Download Full-text

Correlations between alveolar bone microstructure and bone turnover markers in pre- and post-menopausal women

Oral Surgery Oral Medicine Oral Pathology and Oral Radiology ◽

10.1016/j.oooo.2011.10.028 ◽

2013 ◽

Vol 115 (4) ◽

pp. e12-e19 ◽

Cited By ~ 10

Author(s):

Emi Yamashita-Mikami ◽

Mikako Tanaka ◽

Naoki Sakurai ◽

Yoshiaki Arai ◽

Akira Matsuo ◽

...

Keyword(s):

Bone Turnover ◽

Bone Turnover Markers ◽

Alveolar Bone ◽

Bone Microstructure ◽

Menopausal Women ◽

Turnover Markers ◽

Post Menopausal

Download Full-text

Relationship between bone turnover markers and the heel stiffness index measured by quantitative ultrasound in post-menopausal Japanese women

Annals of Human Biology ◽

10.1080/03014460.2019.1607552 ◽

2019 ◽

Vol 46 (4) ◽

pp. 330-334

Author(s):

Takayuki Nishimura ◽

Kazuhiko Arima ◽

Yasuyo Abe ◽

Mitsuo Kanagae ◽

Satoshi Mizukami ◽

...

Keyword(s):

Bone Turnover ◽

Quantitative Ultrasound ◽

Bone Turnover Markers ◽

Japanese Women ◽

Stiffness Index ◽

Turnover Markers ◽

Post Menopausal

Download Full-text

The estimation of the quality of diagnostics of post-menstrual osteoporosis in the Moscow region from the results of a questionnaire study

Problems of Endocrinology ◽

10.14341/probl201258123-28 ◽

2012 ◽

Vol 58 (1) ◽

pp. 23-28 ◽

Cited By ~ 1

Author(s):

A V Dreval' ◽

L A Marchenkova ◽

E A Grigor'eva

Keyword(s):

Spinal Column ◽

Primary Diagnosis ◽

Moscow Region ◽

Questionnaire Study ◽

X Ray ◽

Blood Biochemical ◽

Post Menopausal Osteoporosis ◽

Turnover Markers ◽

Post Menopausal ◽

Menopausal Osteoporosis

The present questionnaire study including female residents of the Moscow region (MR) above the age of 55 years with the confirmed diagnosis of post-menopausal osteoporosis (OP) was designed to obtain an insight into the procedure employed to diagnose post-menopausal OP, categories of specialists involved in diagnostics of this condition, and the methods they use for the purpose. The results of the study indicate that 57.4% of the patients with OP in the first place applied for advice in connection with this disease to an endocrinologist, 19.7% to an orthopedist-traumatologist, 13.% to a rheumatologist, and 4.9% to a neurologist. The endocrinologists referred such patients for bone densitometry and made the diagnosis of post-menopausal osteoporosis in 79% and 70% of the cases respectively. Only a small fraction of orthopedists-traumatologists and rheumatologists practicing in the Moscow region are engaged in diagnostics of post-menopausal osteoporosis as a part of their major activities. At the same time, therapists, gynecologists, and general practitioners do not practically encounter the patients complaining of post-menopausal OP. 38%, 30% and 28% of the respondents reported to have applied to two, three, and one physicians respectively to have the diagnosis of this condition confirmed. However, in the majority of the cases the period from the first visit to a specialist till the establishment of the definitive diagnosis was as long as 1 year (39%). The diagnosis of OP in a small number of the patients was made with the use of a single method, e.g. X-ray densitometry (12%), ultrasonometry (4%), and X-radiography of the skeletal bones (2%). The remaining patients were examined by more than one method; most of them had the primary diagnosis verified by means of X-ray densitometry (77%), blood biochemical analysis (77%), X-radiography of the spinal column (67%), and either by the detection of the serum bone turnover markers or ultrasonometry (16%). The majority of densitometric procedures were performed based at the Moscow Therapeutic and Prophylactic Department and M.F. Vladimirsky Moscow Regional Research Clinical Institute (73% and 17% respectively) for the lack of densitometers in the local medical facilities of the Moscow region.

Download Full-text